Abstract
Aim: To identify the demographics and risk factors in a selected patient population prescribed non‐selective and cyclo‐oxygenase‐2 (COX‐2) selective non‐steroidal anti‐inflammatory drugs (NSAIDs).Method: A structured clinical self‐audit form was distributed in January to March 2001 to 155 interested general practitioners (GPs) in rural Queensland.Results: Seventy‐one GPs participated in the audit and contributed 1417 patient records‐790 patients had received nonselective NSAIDs and 627 had received COX‐2 inhibitors (celecoxib or rofecoxib). Patients who received COX‐2 inhibitors were significantly older, more likely to have clinically important concomitant illness, and more likely to be taking medication known to interact with NSAIDs. They were also twice as likely to have two or more risk factors for adverse effects. The most common reasons for switching from an NSAID to a COX‐2 inhibitor were reported to be a previous side effect from an NSAID (primarily related to gastrointestinal effects) or the doctor's perception of the superior efficacy of COX‐2 inhibitor therapy.Conclusions: This study has shown that COX‐2 inhibitors were used in a distinctly different patient population compared to non‐selective NSAIDs. There were significant variations in the demographics and number of risk factors‐for example, cardiovascular and renal‐between the two identified populations. These differences may be due to doctors selecting COX‐2 inhibitors for patients at high risk of gastrointestinal complications. However, the prescribing pattern may also be partly due to misconceptions about the relative safety and efficacy of COX‐2 inhibitor drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.